Phytochemical-based nanodrugs going beyond the state-of-the-art in cancer management-Targeting cancer stem cells in the framework of predictive, preventive, personalized medicine.
cancer stem cells therapy
nanomedicine
nanoparticles
phytochemicals
plant-derived foods
predictive preventive personalized medicine
primary secondary tertiary care
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
12
2022
accepted:
13
03
2023
medline:
11
4
2023
entrez:
10
4
2023
pubmed:
11
4
2023
Statut:
epublish
Résumé
Cancer causes many deaths worldwide each year, especially due to tumor heterogeneity leading to disease progression and treatment failure. Targeted treatment of heterogeneous population of cells - cancer stem cells is still an issue in protecting affected individuals against associated multidrug resistance and disease progression. Nanotherapeutic agents have the potential to go beyond state-of-the-art approaches in overall cancer management. Specially assembled nanoparticles act as carriers for targeted drug delivery. Several nanodrugs have already been approved by the US Food and Drug Administration (FDA) for treating different cancer types. Phytochemicals isolated from plants demonstrate considerable potential for nanomedical applications in oncology thanks to their antioxidant, anti-inflammatory, anti-proliferative, and other health benefits. Phytochemical-based NPs can enhance anticancer therapeutic effects, improve cellular uptake of therapeutic agents, and mitigate the side effects of toxic anticancer treatments. Per evidence, phytochemical-based NPs can specifically target CSCs decreasing risks of tumor relapse and metastatic disease manifestation. Therefore, this review focuses on current outlook of phytochemical-based NPs and their potential targeting CSCs in cancer research studies and their consideration in the framework of predictive, preventive, and personalized medicine (3PM).
Identifiants
pubmed: 37033601
doi: 10.3389/fphar.2023.1121950
pii: 1121950
pmc: PMC10076662
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1121950Informations de copyright
Copyright © 2023 Koklesova, Jakubikova, Cholujova, Samec, Mazurakova, Šudomová, Pec, Hassan, Biringer, Büsselberg, Hurtova, Golubnitschaja and Kubatka.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Materials (Basel). 2020 Jan 14;13(2):
pubmed: 31947551
Int J Nanomedicine. 2008;3(2):133-49
pubmed: 18686775
Curr Opin Biotechnol. 2007 Dec;18(6):565-71
pubmed: 18160274
Life Sci. 2022 Nov 15;309:121022
pubmed: 36206836
Chem Biol Interact. 2022 Jan 5;351:109745
pubmed: 34774839
Nat Rev Drug Discov. 2021 Feb;20(2):101-124
pubmed: 33277608
EPMA J. 2021 Oct 06;12(4):559-587
pubmed: 34950252
EPMA J. 2021 Sep 13;12(4):403-433
pubmed: 34539937
Int J Mol Sci. 2019 Sep 26;20(19):
pubmed: 31561494
EPMA J. 2022 May 12;13(2):177-193
pubmed: 35578648
Int J Biol Macromol. 2023 Jan 31;226:159-171
pubmed: 36435458
Nanoscale Res Lett. 2021 Dec 5;16(1):173
pubmed: 34866166
Tumour Biol. 2021;43(1):225-247
pubmed: 34542050
Expert Opin Drug Deliv. 2022 Feb;19(2):179-197
pubmed: 35166619
Environ Sci Pollut Res Int. 2020 Jun;27(16):19214-19225
pubmed: 31884543
J Control Release. 2015 Jun 10;207:40-58
pubmed: 25841699
Expert Rev Anticancer Ther. 2015;15(10):1233-55
pubmed: 26402250
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Control Release. 2018 Oct 10;287:78-93
pubmed: 30138716
Cancers (Basel). 2018 Dec 28;11(1):
pubmed: 30597838
Angew Chem Int Ed Engl. 2014 Nov 10;53(46):12320-64
pubmed: 25294565
J Mater Chem B. 2017 Sep 7;5(33):6762-6775
pubmed: 32264326
Int J Biol Macromol. 2021 Aug 31;185:134-152
pubmed: 34147524
Biomacromolecules. 2015 Sep 14;16(9):3042-53
pubmed: 26302089
Colloids Surf B Biointerfaces. 2022 Mar;211:112305
pubmed: 34998178
J Nanobiotechnology. 2018 Sep 19;16(1):71
pubmed: 30231877
J Clin Med. 2021 Oct 31;10(21):
pubmed: 34768644
Acta Biomater. 2022 Dec;154:454-466
pubmed: 36243377
J Control Release. 2021 Jul 10;335:437-448
pubmed: 34081996
Mater Sci Eng C Mater Biol Appl. 2018 Jan 1;82:19-24
pubmed: 29025646
Int J Nanomedicine. 2020 Nov 19;15:9125-9157
pubmed: 33244231
EPMA J. 2022 Mar 1;13(1):1-7
pubmed: 35251382
Nanomedicine (Lond). 2015;10(17):2781-94
pubmed: 26377047
RSC Adv. 2019 Jan 21;9(5):2673-2702
pubmed: 35520490
Mol Cancer. 2017 Feb 16;16(1):41
pubmed: 28209166
Biomaterials. 2015 Jan;37:405-14
pubmed: 25453968
Asian Pac J Cancer Prev. 2014;15(20):8679-84
pubmed: 25374189
J Nanosci Nanotechnol. 2010 Dec;10(12):7906-18
pubmed: 21121278
Hum Gene Ther. 2005 Sep;16(9):1016-27
pubmed: 16149900
Int J Mol Sci. 2020 Dec 31;22(1):
pubmed: 33396561
Theranostics. 2015 Sep 01;5(11):1249-63
pubmed: 26379790
Biomed Microdevices. 2019 Apr 15;21(2):46
pubmed: 30989386
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Colloids Surf B Biointerfaces. 2021 Aug;204:111778
pubmed: 33915380
Int J Nanomedicine. 2020 Jun 19;15:4417-4429
pubmed: 32606686
Cell Commun Signal. 2021 Feb 15;19(1):19
pubmed: 33588867
Molecules. 2022 Oct 18;27(20):
pubmed: 36296595
Front Immunol. 2022 Aug 26;13:922301
pubmed: 36090974
Crit Rev Ther Drug Carrier Syst. 2009;26(6):523-80
pubmed: 20402623
Clin Cancer Res. 2010 Dec 15;16(24):6139-49
pubmed: 20876255
Mater Sci Eng C Mater Biol Appl. 2019 Sep;102:362-372
pubmed: 31147008
Methods Mol Biol. 2018;1831:59-67
pubmed: 30051425
Materials (Basel). 2021 Mar 12;14(6):
pubmed: 33809119
EPMA J. 2022 Apr 14;13(2):315-334
pubmed: 35437454
Pharm Res. 2021 May;38(5):851-871
pubmed: 33982225
Chem Biol Interact. 2018 Nov 1;295:1-12
pubmed: 30048623
Nat Nanotechnol. 2021 Jan;16(1):104-113
pubmed: 33437035
Biomed Res Int. 2020 Dec 28;2020:3189217
pubmed: 33457406
Drugs. 2020 Jul;80(10):1007-1018
pubmed: 32557396
J Biomed Nanotechnol. 2016 Jul;12(7):1463-77
pubmed: 29337484
Int J Nanomedicine. 2020 Sep 10;15:6649-6658
pubmed: 32982224
Environ Sci Pollut Res Int. 2022 Jul;29(31):47539-47548
pubmed: 35182347
Cancers (Basel). 2020 Aug 26;12(9):
pubmed: 32859058
Blood. 2008 Dec 15;112(13):4793-807
pubmed: 19064739
Carbohydr Polym. 2021 Oct 1;269:118294
pubmed: 34294320
Adv Protein Chem Struct Biol. 2021;125:275-305
pubmed: 33931143
Medicines (Basel). 2019 Mar 14;6(1):
pubmed: 30875823
Cancer Immunol Immunother. 2019 May;68(5):799-812
pubmed: 30770959
Nanomaterials (Basel). 2021 Nov 05;11(11):
pubmed: 34835741
Adv Drug Deliv Rev. 2010 Mar 8;62(3):339-45
pubmed: 19909777
Br J Radiol. 2015 Oct;88(1054):20150207
pubmed: 25969868
J Photochem Photobiol B. 2017 May;170:58-64
pubmed: 28390259
Biomed Pharmacother. 2021 Jan;133:110909
pubmed: 33227701
Int J Nanomedicine. 2018 Dec 11;13:8487-8506
pubmed: 30587973
Front Oncol. 2022 Jan 19;11:819329
pubmed: 35127533
Ther Deliv. 2011 Aug;2(8):1001-14
pubmed: 22506095
Nutrients. 2010 Jun;2(6):611-25
pubmed: 22254045
Colloids Surf B Biointerfaces. 2018 Jul 1;167:8-19
pubmed: 29625422
Int J Nanomedicine. 2021 May 11;16:3293-3315
pubmed: 34007178
Environ Health Perspect. 2006 Dec;114(12):1818-25
pubmed: 17185269
Target Oncol. 2015 Dec;10(4):467-85
pubmed: 25989948
Front Chem. 2022 Oct 13;10:1018759
pubmed: 36311430
Nat Commun. 2016 Nov 10;7:13325
pubmed: 27830705
EPMA J. 2021 Mar 4;12(1):27-40
pubmed: 33686350
J Nutr. 2004 Dec;134(12 Suppl):3479S-3485S
pubmed: 15570057
Drug Deliv. 2019 Dec;26(1):1002-1016
pubmed: 31571501
Pharmaceutics. 2021 Nov 05;13(11):
pubmed: 34834286
Naunyn Schmiedebergs Arch Pharmacol. 2023 Mar;396(3):533-546
pubmed: 36418466
Biosci Rep. 2020 Apr 30;40(4):
pubmed: 32163546
Int J Nanomedicine. 2019 Jun 18;14:4413-4428
pubmed: 31417252
Oncologist. 2020 Feb;25(2):123-131
pubmed: 32043793
Materials (Basel). 2022 Jan 21;15(3):
pubmed: 35160749
Int J Hyperthermia. 2018 Dec;34(8):1316-1328
pubmed: 29353516
J Control Release. 2012 Jun 10;160(2):117-34
pubmed: 22484195
EPMA J. 2020 Jul 30;11(3):377-398
pubmed: 32843908
N Engl J Med. 2019 Feb 14;380(7):617-628
pubmed: 30516102
Paediatr Drugs. 2010 Jun;12(3):141-53
pubmed: 20481644
Biomaterials. 2015 Dec;72:74-89
pubmed: 26344365
Adv Enzyme Regul. 2001;41:189-207
pubmed: 11384745
Int J Mol Sci. 2022 Dec 10;23(24):
pubmed: 36555306
Sci Rep. 2018 Jan 18;8(1):1084
pubmed: 29348534
J Nutr Biochem. 2021 Jun;92:108624
pubmed: 33705943
Nano Rev. 2012;3:
pubmed: 23240070
Bioconjug Chem. 2018 Oct 17;29(10):3495-3502
pubmed: 30252441
EPMA J. 2021 Aug 17;12(3):243-264
pubmed: 34422142
EPMA J. 2020 May 29;11(2):261-287
pubmed: 32547652
Am Soc Clin Oncol Educ Book. 2016;35:e64-70
pubmed: 27249772
Molecules. 2020 Jun 22;25(12):
pubmed: 32580417
Adv Sci (Weinh). 2022 Aug;9(22):e2105077
pubmed: 35717675
Front Pharmacol. 2022 Jan 10;13:847048
pubmed: 35222052
Int J Nanomedicine. 2020 Jan 13;15:181-197
pubmed: 32021173
Semin Cancer Biol. 2021 Feb;69:200-211
pubmed: 31374244
Immunotherapy. 2018 Sep;10(13):1175-1188
pubmed: 30236026
J Control Release. 2022 Nov;351:37-49
pubmed: 36089170
RSC Adv. 2019 Nov 13;9(63):37067-37078
pubmed: 35539080
Cancer Lett. 2018 Oct 1;433:53-64
pubmed: 29960048
Biomaterials. 2016 Sep;101:321-40
pubmed: 27318094
Pharmacol Res. 2020 Jun;156:104753
pubmed: 32209363
Bioorg Med Chem. 2020 Feb 15;28(4):115306
pubmed: 31926774
EPMA J. 2022 Jul 8;13(3):461-486
pubmed: 35821883
Curr Pharm Biotechnol. 2020;21(3):206-218
pubmed: 31573882
Front Bioeng Biotechnol. 2019 Oct 22;7:293
pubmed: 31696114
Curr Med Chem Anticancer Agents. 2002 Nov;2(6):715-26
pubmed: 12678722
Drug Resist Updat. 2019 Sep;46:100645
pubmed: 31585396
Oncotarget. 2017 Aug 24;8(65):108624-108642
pubmed: 29312556
Int J Hyperthermia. 2016;32(1):76-88
pubmed: 26757879
Nanotechnology. 2020 May 1;31(18):185102
pubmed: 31952056
Mol Cancer. 2021 Feb 25;20(1):41
pubmed: 33632261
EPMA J. 2021 May 17;12(2):155-176
pubmed: 34025826
J Immunother Cancer. 2019 Feb 8;7(1):38
pubmed: 30736848
Int J Nanomedicine. 2020 Aug 13;15:6033-6066
pubmed: 32884261
Cell Tissue Res. 2018 Dec;374(3):427-438
pubmed: 30302547